United States · Markets & Finance · The Motley Fool

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield

Published by The Motley Fool · United States 9 h ago

As it stands, roughly one-third of Pfizer's revenue is subject to patent expirations over the next couple of years. It's nothing to dismiss. Largely lost in the matter, however,…

Read the full article on The Motley Fool Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Decrypt

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

CNBC

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield

Share

Also worth reading

'Uptober' Starts Green as Bitcoin ETFs Draw $134 Million

Private Equity Firms Double Down on Fossil Fuels

American Airlines adds cash-and-miles bookings as loyalty battle heats up

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

This NYC startup requires 4 days in office but just let everyone work remote for a whole month